Ankylosing Spondylitis treatment with Biologic medication
Dear Croydon Health Services NHS Trust,
I am seeking the following information under the freedom of information act.
For patients diagnosed with Ankylosing Spondylitis and receiving treatment on Biologic medication, I’d like to know the number of patients on the various drugs (including the biosimilar brand names) that are licensed for Ankylosing Spondylitis between January 2021 and March 2025
Yours faithfully,
Adam
Dear Croydon Health Services NHS Trust,
I am updating this request to make sure it complies and is a valid FOI request by adding my full name.
Yours faithfully,
Adam Fish
Thank you for your FOI request which is now being considered. Your
reference number is: FOI: 7561, and should be quoted in all your future
correspondence relating to this request.
It is anticipated that a response will be communicated to you within 20
working days in compliance with the Freedom of Information Act 2000.
Kind regards
FOI Team
Croydon Health Services NHS Trust
Email: [1][email address]
Dear FOI (CROYDON HEALTH SERVICES NHS TRUST),
This FOI request is outstanding and now overdue by some days. Is it possible to get this looked into and provide the information that I’ve requested?
Yours sincerely,
Adam Fish
Dear Adam,
FOI REFERENCE NUMBER: 7561
Thank you for your email of 20^th March 2025 requesting information Under
the Freedom of Information Act (FOIA) 2000. I set out below your request
together with our response:
Dear Croydon Health Services NHS Trust,
I am seeking the following information under the freedom of information
act.
For patients diagnosed with Ankylosing Spondylitis and receiving treatment
on Biologic medication, I’d like to know the number of patients on the
various drugs (including the biosimilar brand names) that are licensed for
Ankylosing Spondylitis between January 2021 and March 2025
Answers follow:
Adalimumab 122 patients (brands include Humira, Idacio or Yuflyma) We
cannot split this by brand as we do not hold historic data.
Certolizumab <10 patients (Cimzia)
Golimumab <10 patients (Simponi)
Secukinumab 24 patients (Cosentyx)
The information supplied to you continues to be protected by the
Copyright, Designs and Patents Act 1988. You are free to use it for your
own purposes, including any non-commercial research that you are doing and
for the purposes of news reporting. Any other reuse, for example
commercial publication, would require the permission of the copyright
holder which must be expressly given.
If you are unhappy with this response the Trust has a formal Complaints
Procedure which you may use by writing to The Medical Director,
[1][Croydon Health Services NHS Trust request email]. If you remain
unsatisfied you may contact the Information Commissioner’s Office at
Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF. Further
details of this procedure can be found online at - [2]https://ico.org.uk/.
Thank you for your interest in Croydon Health Services NHS Trust.
Yours sincerely
FOI Team
Croydon Health Services NHS Trust
Email: [3][email address]
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now